JP2014510045A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014510045A5 JP2014510045A5 JP2013552741A JP2013552741A JP2014510045A5 JP 2014510045 A5 JP2014510045 A5 JP 2014510045A5 JP 2013552741 A JP2013552741 A JP 2013552741A JP 2013552741 A JP2013552741 A JP 2013552741A JP 2014510045 A5 JP2014510045 A5 JP 2014510045A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- multivesicular liposome
- hyaluronan degrading
- degrading enzyme
- multivesicular
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 24
- 229920002674 hyaluronan Polymers 0.000 claims 21
- 239000002502 liposome Substances 0.000 claims 20
- KIUKXJAPPMFGSW-MNSSHETKSA-N Hyaluronan Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 claims 16
- 229940099552 Hyaluronan Drugs 0.000 claims 16
- 102000004190 Enzymes Human genes 0.000 claims 15
- 108090000790 Enzymes Proteins 0.000 claims 15
- 230000000593 degrading Effects 0.000 claims 14
- 229940088598 Enzyme Drugs 0.000 claims 12
- 150000002632 lipids Chemical class 0.000 claims 10
- 102000001974 Hyaluronidase Human genes 0.000 claims 5
- 108010074224 Hyaluronoglucosaminidase Proteins 0.000 claims 5
- 150000001413 amino acids Chemical class 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 5
- 229960003160 hyaluronic acid Drugs 0.000 claims 5
- 229960002773 hyaluronidase Drugs 0.000 claims 5
- MAKUBRYLFHZREJ-JWBQXVCJSA-M sodium;(2S,3S,4R,5R,6R)-3-[(2S,3R,5S,6R)-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylate Chemical compound [Na+].CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C([O-])=O)O[C@@H](O)[C@H](O)[C@H]1O MAKUBRYLFHZREJ-JWBQXVCJSA-M 0.000 claims 5
- 102100004182 SPAM1 Human genes 0.000 claims 4
- 101710016618 SPAM1 Proteins 0.000 claims 4
- 230000001264 neutralization Effects 0.000 claims 4
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims 3
- 229940020899 hematological Enzymes Drugs 0.000 claims 3
- 229920000642 polymer Polymers 0.000 claims 3
- HVYWMOMLDIMFJA-DPAQBDIFSA-N (3β)-Cholest-5-en-3-ol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 2
- ZAKBPRIDLSBYQQ-VHSXEESVSA-N 1,2-diacyl-sn-glycero-3-phospho-(1'-sn-glycerol) Chemical compound CC(=O)OC[C@@H](OC(C)=O)COP(O)(=O)OC[C@@H](O)CO ZAKBPRIDLSBYQQ-VHSXEESVSA-N 0.000 claims 2
- 229940030495 ANTIANDROGEN SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM Drugs 0.000 claims 2
- 108010043024 Botulinum Toxins Proteins 0.000 claims 2
- 102100020232 GALNS Human genes 0.000 claims 2
- 101700032815 GALNS Proteins 0.000 claims 2
- 101700063555 HYAL Proteins 0.000 claims 2
- 102000004317 Lyases Human genes 0.000 claims 2
- 108090000856 Lyases Proteins 0.000 claims 2
- UNJJBGNPUUVVFQ-ZJUUUORDSA-N Phosphatidylserine Chemical compound CCCC(=O)O[C@H](COC(=O)CC)COP(O)(=O)OC[C@H](N)C(O)=O UNJJBGNPUUVVFQ-ZJUUUORDSA-N 0.000 claims 2
- 239000002160 alpha blocker Substances 0.000 claims 2
- 230000002280 anti-androgenic Effects 0.000 claims 2
- 239000000051 antiandrogen Substances 0.000 claims 2
- 230000021615 conjugation Effects 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 239000000839 emulsion Substances 0.000 claims 2
- 239000003960 organic solvent Substances 0.000 claims 2
- 150000008103 phosphatidic acids Chemical class 0.000 claims 2
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims 2
- 150000008104 phosphatidylethanolamines Chemical class 0.000 claims 2
- 229920001184 polypeptide Polymers 0.000 claims 2
- 239000002904 solvent Substances 0.000 claims 2
- XVTUQDWPJJBEHJ-KZCWQMDCSA-N tetrastearoyl cardiolipin Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCCCC)CO[P@@](O)(=O)OCC(O)CO[P@](O)(=O)OC[C@H](OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC XVTUQDWPJJBEHJ-KZCWQMDCSA-N 0.000 claims 2
- 239000002677 5-alpha reductase inhibitor Substances 0.000 claims 1
- 229940107161 Cholesterol Drugs 0.000 claims 1
- 229920002307 Dextran Polymers 0.000 claims 1
- JWJOTENAMICLJG-QWBYCMEYSA-N Dutasteride Chemical compound O=C([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)N[C@@H]4CC3)C)CC[C@@]21C)NC1=CC(C(F)(F)F)=CC=C1C(F)(F)F JWJOTENAMICLJG-QWBYCMEYSA-N 0.000 claims 1
- DBEPLOCGEIEOCV-WSBQPABSSA-N Finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 claims 1
- 102000004157 Hydrolases Human genes 0.000 claims 1
- 108090000604 Hydrolases Proteins 0.000 claims 1
- LKQLRGMMMAHREN-YJFXYUILSA-N N-stearoylsphingosine-1-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)N[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)[C@H](O)\C=C\CCCCCCCCCCCCC LKQLRGMMMAHREN-YJFXYUILSA-N 0.000 claims 1
- 229940053031 botulinum toxin Drugs 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 235000012000 cholesterol Nutrition 0.000 claims 1
- 230000001809 detectable Effects 0.000 claims 1
- BIABMEZBCHDPBV-UHFFFAOYSA-N dipalmitoyl phosphatidylglycerol Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCCCCCCCCCC BIABMEZBCHDPBV-UHFFFAOYSA-N 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229940079593 drugs Drugs 0.000 claims 1
- 229960004199 dutasteride Drugs 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 229960004039 finasteride Drugs 0.000 claims 1
- 230000003301 hydrolyzing Effects 0.000 claims 1
- 238000001802 infusion Methods 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 150000003905 phosphatidylinositols Chemical class 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 claims 1
- 239000001294 propane Substances 0.000 claims 1
- 150000003626 triacylglycerols Chemical class 0.000 claims 1
Claims (31)
- 中性脂質と、
両親媒性脂質と
ヒアルロナン分解酵素と
を含む多小胞リポソームであって、ヒアルロナン分解酵素の濃度は、0.1mg/mL〜1mg/mLの間もしくはおよそその間である、多小胞リポソーム。 - ヒアルロン酸をさらに含む、請求項1に記載の多小胞リポソーム。
- 中性脂質と、
両親媒性脂質と
ヒアルロナン分解酵素と
ヒアルロン酸と
を含む多小胞リポソーム。 - ヒアルロナン分解酵素が、リポソーム内にカプセル封入されている、請求項1から3のいずれかに記載の多小胞リポソーム。
- ヒアルロナン分解酵素が、ヒアルロニダーゼ、コンドロイチナーゼまたはリアーゼである、請求項1から4のいずれかに記載の多小胞リポソーム。
- ヒアルロニダーゼが、PH20ヒアルロニダーゼである、請求項1から4のいずれかに記載の多小胞リポソーム。
- 可溶性PH20が、配列番号4〜9および47〜48のいずれかに示されるアミノ酸の配列または配列番号4〜9および47〜48のいずれかと少なくとも95%のアミノ酸配列同一性を示すアミノ酸の配列を含有するポリペプチドの中から選択される、請求項6に記載の多小胞リポソーム。
- ヒアルロナン分解酵素が、ポリマーとのコンジュゲーションによって修飾されているか、または標識または検出可能な部分と直接または間接的に連結されている、請求項1から7のいずれかに記載の多小胞リポソーム。
- ヒアルロン酸の濃度が、0.05mg/mL〜50mg/mLであるか、もしくはその間である、請求項3から8のいずれかに記載の多小胞リポソーム。
- 中性脂質が、ジグリセリドまたはトリグリセリドである、請求項1から9のいずれかに記載の多小胞リポソーム。
- 両親媒性脂質が、ホスファチジルグリセロール(PG)、カルジオリピン(CL)、ホスファチジルセリン(PS)、ホスファチジン酸(PA)、ホスファチジルイノシトール、ホスファチジルコリン(PC)、ホスファチジルエタノールアミン(PE)、スフィンゴミエリンまたはジアシルトリメチルアンモニウムプロパン(DITAP)である、請求項1から10のいずれかに記載の多小胞リポソーム。
- DPPGまたはコレステロールの1つまたは両方をさらに含む、請求項1から12のいずれかに記載の多小胞リポソーム。
- 治療薬を含む、請求項1から12のいずれかに記載の多小胞リポソーム。
- 治療薬が、抗アンドロゲン剤、α遮断薬、ボツリヌス毒素および加水分解酵素の中から選択される良性前立腺肥大症を治療するための薬剤である、請求項13に記載の多小胞リポソーム。
- a)ヒアルロナン分解酵素を2mg/mL未満の濃度で含む第1の水性成分を形成する工程と、
b)少なくとも1種の有機溶媒と、少なくとも1種の両親媒性脂質と、少なくとも1種の中性脂質とを含む脂質成分を形成する工程と、
c)第1の水性成分および脂質成分からエマルジョンを形成する工程と、
d)エマルジョンを第2の水性成分中に分散して溶媒小球を形成する工程と、
e)溶媒小球から有機溶媒を除去して、第2の水性成分中に懸濁された多小胞リポソームを形成する工程と
を含むプロセスによって製造されるか、またはプロセスによって得ることができる多小胞リポソームであって、得られる多小胞リポソームは、0.1mg/mL〜1mg/mLのヒアルロナン分解酵素を含む、多小胞リポソーム。 - 医薬上許容される担体中に請求項1から14のいずれかに記載の多小胞リポソームを含む、組成物。
- 請求項15に記載の組成物を含む第1の組成物と、
治療薬を含む第2の組成物と
を含む、組合せ。 - 治療薬が、抗アンドロゲン剤、α遮断薬、ボツリヌス毒素および加水分解酵素の中から選択される良性前立腺肥大症を治療するために適している薬剤である、請求項16に記載の組成物または請求項17に記載の組合せ。
- 治療薬が、フィナステリドまたはデュタステリドである5α−レダクターゼ阻害剤である、請求項16から18のいずれかに記載の組成物または組合せ。
- ヒアルロナン分解酵素と、
ヒアルロン酸と
を含み、それによって、ヒアルロナン分解酵素が、ヒアルロニダーゼ活性の少なくとも50%を、28℃〜32℃で少なくとも6カ月、または2℃〜8℃で少なくとも1年保持する、組成物であって、ヒアルロナン分解酵素の濃度は少なくとも50U/mLである、組成物。 - ヒアルロナン分解酵素が、ヒアルロニダーゼ、コンドロイチナーゼまたはリアーゼである、請求項20に記載の組成物。
- ヒアルロニダーゼが、PH20ヒアルロニダーゼである、請求項20または21に記載の組成物。
- PH20が、配列番号4〜9および47〜48のいずれかに示されるアミノ酸の配列を含有するポリペプチドまたは配列番号4〜9および47〜48のいずれかと少なくとも95%の配列同一性を示すアミノ酸の配列の中から選択される、請求項22に記載の組成物。
- ヒアルロナン分解酵素が、ポリマーとのコンジュゲーションによって修飾されている、請求項20から23のいずれかに記載の組成物。
- ポリマーが、PEGまたはデキストランである、請求項24に記載の組成物。
- ヒアルロナン分解酵素の濃度が、100U/mL〜1000U/mLであるか、またはおよそその間である、請求項20から25のいずれかに記載の組成物。
- ヒアルロン酸の濃度が、1mg/mL〜100mg/mLであるか、またはおよそその間である、請求項20から26のいずれかに記載の組成物。
- 0.5mL〜50mLの間またはおよそ0.5mL〜50mLの容量で製剤される、請求項20から27のいずれかに記載の組成物。
- ヒアルロナン関連疾患または状態の治療において使用するための、請求項15から28のいずれかに記載の組成物または組合せ。
- ヒアルロナン関連疾患または状態が、良性前立腺肥大症である、請求項29に記載の組成物。
- 前立腺内注射または注入用に製剤される、請求項29または請求項30に記載の組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161462875P | 2011-02-08 | 2011-02-08 | |
US61/462,875 | 2011-02-08 | ||
PCT/US2012/024376 WO2012109387A1 (en) | 2011-02-08 | 2012-02-08 | Composition and lipid formulation of a hyaluronan-degrading enzyme and the use thereof for treatment of benign prostatic hyperplasia |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017030692A Division JP6403819B2 (ja) | 2011-02-08 | 2017-02-22 | ヒアルロナン分解酵素の脂質製剤 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2014510045A JP2014510045A (ja) | 2014-04-24 |
JP2014510045A5 true JP2014510045A5 (ja) | 2015-04-09 |
Family
ID=45607419
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013552741A Pending JP2014510045A (ja) | 2011-02-08 | 2012-02-08 | ヒアルロナン分解酵素の組成物および脂質製剤ならびに良性前立腺肥大症の治療のためのその使用 |
JP2017030692A Active JP6403819B2 (ja) | 2011-02-08 | 2017-02-22 | ヒアルロナン分解酵素の脂質製剤 |
JP2018131504A Pending JP2018172429A (ja) | 2011-02-08 | 2018-07-11 | ヒアルロナン分解酵素の組成物および脂質製剤ならびに良性前立腺肥大症の治療のためのその使用 |
JP2020108943A Active JP6831488B2 (ja) | 2011-02-08 | 2020-06-24 | ヒアルロナン分解酵素の脂質製剤 |
Family Applications After (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017030692A Active JP6403819B2 (ja) | 2011-02-08 | 2017-02-22 | ヒアルロナン分解酵素の脂質製剤 |
JP2018131504A Pending JP2018172429A (ja) | 2011-02-08 | 2018-07-11 | ヒアルロナン分解酵素の組成物および脂質製剤ならびに良性前立腺肥大症の治療のためのその使用 |
JP2020108943A Active JP6831488B2 (ja) | 2011-02-08 | 2020-06-24 | ヒアルロナン分解酵素の脂質製剤 |
Country Status (5)
Country | Link |
---|---|
US (1) | US9333244B2 (ja) |
EP (2) | EP2672958A1 (ja) |
JP (4) | JP2014510045A (ja) |
ES (1) | ES2634669T3 (ja) |
WO (1) | WO2012109387A1 (ja) |
Families Citing this family (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7871607B2 (en) | 2003-03-05 | 2011-01-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
PL2405015T3 (pl) * | 2003-03-05 | 2016-09-30 | Rozpuszczalna glikoproteina o aktywności hialuronizady (sHASEGP), sposób jej wytwarzania, jej zastosowania i zawierające ją kompozycje farmaceutyczne | |
US9044477B2 (en) * | 2007-12-12 | 2015-06-02 | Allergan, Inc. | Botulinum toxin formulation |
KR20160052812A (ko) | 2008-04-14 | 2016-05-12 | 할로자임, 아이엔씨 | 히알루로난 관련 질환 및 상태 치료용 변형된 히알루로니다제 및 그 용도 |
TWI394580B (zh) | 2008-04-28 | 2013-05-01 | Halozyme Inc | 超快起作用胰島素組成物 |
EA036569B1 (ru) | 2008-12-09 | 2020-11-24 | Галозим, Инк. | Способ получения полипептида гиалуронидазы ph20 |
DK2477603T3 (en) | 2009-09-17 | 2016-06-13 | Baxalta Inc | STABLE CO-DEVELOPMENT OF hyaluronidase and Immunoglobulin, AND METHODS OF USE THEREOF |
EP2595624B1 (en) | 2010-07-20 | 2018-01-31 | Halozyme, Inc. | Methods of treatment or prevention of the adverse side-effects associated with administration of an anti-hyaluronan agent |
ES2634669T3 (es) | 2011-02-08 | 2017-09-28 | Halozyme, Inc. | Composición y formulación lipídica de una enzima de degradación de hialuronano y uso de la misma para el tratamiento de la hiperplasia benigna de próstata |
US9993529B2 (en) | 2011-06-17 | 2018-06-12 | Halozyme, Inc. | Stable formulations of a hyaluronan-degrading enzyme |
EA030440B1 (ru) | 2011-10-24 | 2018-08-31 | Галозим, Инк. | Сопровождающая диагностика для терапии антигиалуронановым агентом и способы ее применения |
RS59703B1 (sr) | 2011-12-30 | 2020-01-31 | Halozyme Inc | Varijante ph20 polipeptida, njihove formulacije i upotrebe |
CA2986512C (en) | 2012-04-04 | 2022-05-17 | Halozyme, Inc. | Combination therapy with an anti-hyaluronan agent and a tumor-targeted taxane |
US9375433B2 (en) | 2012-09-26 | 2016-06-28 | Tangent Reprofiling Limited | Modulators of androgen synthesis |
CA2886132C (en) * | 2012-09-26 | 2023-03-21 | Tangent Reprofiling Limited | Modulators of androgen synthesis |
WO2014062856A1 (en) | 2012-10-16 | 2014-04-24 | Halozyme, Inc. | Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods |
US20140371417A1 (en) * | 2013-04-26 | 2014-12-18 | Genomatica, Inc. | Microorganisms and methods for production of 4-hydroxybutyrate, 1,4-butanediol and related compounds |
MX2016001030A (es) | 2013-07-23 | 2016-10-07 | Allergan Inc | Métodos y composiciones que comprenden desmopresina en combinación con un agonista del receptor beta 3-adrenérgico. |
TR201807778T4 (tr) * | 2014-01-17 | 2018-06-21 | Fundacio Inst Catala De Nanociencia I Nanotecnologia | Lipozom bazlı immünoterapi. |
WO2016011262A1 (en) * | 2014-07-16 | 2016-01-21 | New York University | Use of hyaluronidase for treatment of muscle stiffness |
KR101809908B1 (ko) | 2014-07-21 | 2018-01-25 | 주식회사 종근당 | 5-알파환원효소억제제를 포함하는 조성물 |
PT3186281T (pt) | 2014-08-28 | 2019-07-10 | Halozyme Inc | Terapia de combinação com uma enzima de degradação de hialuronano e um inibidor de pontos de verificação imunológica |
CA3203273A1 (en) | 2014-10-14 | 2016-04-21 | Halozyme, Inc. | Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same |
US10286033B2 (en) * | 2014-11-20 | 2019-05-14 | Serenity Pharmaceuticals, Llc | Methods and compositions comprising desmopressin in combination with an alpha-adrenergic receptor antagonist |
US20160361380A1 (en) * | 2015-06-12 | 2016-12-15 | Nymox Corporation | Combination compositions for treating disorders requiring removal or destruction of unwanted cellular proliferations |
JP6661319B2 (ja) * | 2015-09-28 | 2020-03-11 | 小林製薬株式会社 | リポソーム |
KR102069670B1 (ko) * | 2017-03-02 | 2020-01-23 | 단디바이오사이언스 주식회사 | 면역활성물질을 포함하는 다중도메인캡슐, 이의 제조방법, 및 이를 포함하는 면역조절 조성물 |
CN111356446A (zh) * | 2017-07-07 | 2020-06-30 | Dfb医药有限责任公司 | 通过直接注射抗肿瘤剂治疗包括良性前列腺增生(bph)的增生性组织生长 |
WO2019222435A1 (en) | 2018-05-16 | 2019-11-21 | Halozyme, Inc. | Methods of selecting subjects for combination cancer therapy with a polymer-conjugated soluble ph20 |
US11541105B2 (en) | 2018-06-01 | 2023-01-03 | The Research Foundation For The State University Of New York | Compositions and methods for disrupting biofilm formation and maintenance |
WO2020145415A1 (ko) * | 2019-01-07 | 2020-07-16 | 부산대학교 산학협력단 | 혈관-뇌장벽 투과성을 증진시키는 w/o/w형 트리올레인 에멀전을 이용한 약물 전달 플랫폼 |
WO2022072383A1 (en) | 2020-09-30 | 2022-04-07 | Cercacor Laboratories, Inc. | Insulin formulations and uses in infusion devices |
US11033495B1 (en) | 2021-01-22 | 2021-06-15 | Pacira Pharmaceuticals, Inc. | Manufacturing of bupivacaine multivesicular liposomes |
US20220304932A1 (en) * | 2021-01-22 | 2022-09-29 | Pacira Pharmaceuticals, Inc. | Manufacturing of bupivacaine multivesicular liposomes |
WO2022159564A1 (en) * | 2021-01-22 | 2022-07-28 | Pacira Pharmaceuticals, Inc. | Manufacturing of bupivacaine multivesicular liposomes |
US11357727B1 (en) | 2021-01-22 | 2022-06-14 | Pacira Pharmaceuticals, Inc. | Manufacturing of bupivacaine multivesicular liposomes |
US11278494B1 (en) * | 2021-01-22 | 2022-03-22 | Pacira Pharmaceuticals, Inc. | Manufacturing of bupivacaine multivesicular liposomes |
CN113842356A (zh) * | 2021-10-21 | 2021-12-28 | 药大制药有限公司 | 一种比沙可啶儿童栓及其制备方法 |
TR2021021772A2 (tr) * | 2021-12-30 | 2022-01-21 | Misra Berna Oezdemir | Doğal ve sürdürülebi̇li̇r bi̇r kayganlaştirici jel formülasyonu ve üreti̇m yöntemi̇ |
WO2024073588A1 (en) * | 2022-09-28 | 2024-04-04 | Board Of Regents, The University Of Texas System | Respiratory dry powder delivery |
Family Cites Families (149)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3539794A (en) | 1967-09-12 | 1970-11-10 | American Cyanamid Co | Self-contained chemiluminescent lighting device |
US3710795A (en) | 1970-09-29 | 1973-01-16 | Alza Corp | Drug-delivery device with stretched, rate-controlling membrane |
US3875229A (en) | 1972-11-24 | 1975-04-01 | Schering Corp | Substituted carboxanilides |
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
FR2329276A1 (fr) | 1975-10-29 | 1977-05-27 | Roussel Uclaf | Nouvelles imidazolidines substituees, procede de preparation, application comme medicament et compositions les renfermant |
US4002531A (en) | 1976-01-22 | 1977-01-11 | Pierce Chemical Company | Modifying enzymes with polyethylene glycol and product produced thereby |
US4078052A (en) | 1976-06-30 | 1978-03-07 | The United States Of America As Represented By The Secretary Of Health, Education And Welfare | Large unilamellar vesicles (LUV) and method of preparing same |
CH624011A5 (ja) | 1977-08-05 | 1981-07-15 | Battelle Memorial Institute | |
EP0002309B1 (en) | 1977-10-12 | 1982-12-01 | Imperial Chemical Industries Plc | Acylanilides, process for their manufacture and pharmaceutical and veterinary compositions containing them |
SU787035A1 (ru) | 1978-01-11 | 1980-12-15 | Всесоюзный научно-исследовательский и испытательный институт медицинской техники | Устройство дл введени лекарственных препаратов |
US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
US4377584A (en) | 1978-04-13 | 1983-03-22 | Merck & Co., Inc. | 4-Aza-17β-substituted-5α-androstan-3-one-reductase inhibitors |
IT1111367B (it) | 1978-11-17 | 1986-01-13 | Serono Ist Farm | Processo per la preparazione estemporanea di liposomi e liposomi cosi' ottenuti |
US4202314A (en) | 1978-11-20 | 1980-05-13 | Busygin Valery P | Device for injection of medicinal preparations |
US4220735A (en) | 1978-12-18 | 1980-09-02 | General Electric Company | Modified polyester compositions |
US4310506A (en) | 1979-02-22 | 1982-01-12 | California Institute Of Technology | Means of preparation and applications of liposomes containing high concentrations of entrapped ionic species |
NZ197008A (en) | 1980-05-22 | 1984-10-19 | Ici Ltd | Acylanilide derivatives and pharmaceutical compositions |
US4394372A (en) | 1980-12-22 | 1983-07-19 | The Procter & Gamble Company | Process for making lipid membrane structures |
DE3278101D1 (en) | 1981-08-10 | 1988-03-17 | Duphar Int Res | Automatic injection syringe |
FR2521565B1 (fr) | 1982-02-17 | 1985-07-05 | Dior Sa Parfums Christian | Melange pulverulent de constituants lipidiques et de constituants hydrophobes, procede pour le preparer, phases lamellaires lipidiques hydratees et procede de fabrication, compositions pharmaceutiques ou cosmetiques comportant des phases lamellaires lipidiques hydratees |
US4522803A (en) | 1983-02-04 | 1985-06-11 | The Liposome Company, Inc. | Stable plurilamellar vesicles, their preparation and use |
LU88769I2 (fr) | 1982-07-23 | 1996-11-05 | Zeneca Ltd | Bicalutamide et ses sels et esters pharmaceutiquement acceptables (Casodex (R)) |
US4485054A (en) | 1982-10-04 | 1984-11-27 | Lipoderm Pharmaceuticals Limited | Method of encapsulating biologically active materials in multilamellar lipid vesicles (MLV) |
US4859681A (en) | 1984-02-27 | 1989-08-22 | Merck & Co., Inc. | 17 α-Acyl-4-aza-5a-androst-1-en-3-ones as 5 alpha-reductase inhibitors |
US4760071A (en) | 1984-02-27 | 1988-07-26 | Merck & Co., Inc. | 17β-N-monosubstituted carbamoyl-4-aza-5α-androst-1-en-3-ones which are active as testosterone 5α-reductase inhibitors |
US4952496A (en) | 1984-03-30 | 1990-08-28 | Associated Universities, Inc. | Cloning and expression of the gene for bacteriophage T7 RNA polymerase |
WO1995024221A1 (en) | 1986-08-18 | 1995-09-14 | The Dow Chemical Company | Bioactive and/or targeted dendrimer conjugates |
US5723147A (en) | 1987-02-23 | 1998-03-03 | Depotech Corporation | Multivesicular liposomes having a biologically active substance encapsulated therein in the presence of a hydrochloride |
SE457417B (sv) | 1987-04-14 | 1988-12-27 | Astra Meditec Ab | Automatisk tvaakammarspruta, foerfarande foer blandning och injicering med sprutan samt ampull foer tvaakammarspruta |
US5033252A (en) | 1987-12-23 | 1991-07-23 | Entravision, Inc. | Method of packaging and sterilizing a pharmaceutical product |
US5052558A (en) | 1987-12-23 | 1991-10-01 | Entravision, Inc. | Packaged pharmaceutical product |
US5041292A (en) | 1988-08-31 | 1991-08-20 | Theratech, Inc. | Biodegradable hydrogel matrices for the controlled release of pharmacologically active agents |
US5116615A (en) | 1989-01-27 | 1992-05-26 | Immunolytics, Inc. | Method for treating benign prostatic hypertrophy |
WO1990008555A1 (en) | 1989-01-27 | 1990-08-09 | Immunolytics, Inc. | Composition and method for treating benign prostatic hypertrophy |
US5324844A (en) | 1989-04-19 | 1994-06-28 | Enzon, Inc. | Active carbonates of polyalkylene oxides for modification of polypeptides |
US5122614A (en) | 1989-04-19 | 1992-06-16 | Enzon, Inc. | Active carbonates of polyalkylene oxides for modification of polypeptides |
US5919665A (en) | 1989-10-31 | 1999-07-06 | Ophidian Pharmaceuticals, Inc. | Vaccine for clostridium botulinum neurotoxin |
CA2106301C (en) | 1991-03-18 | 1999-04-06 | Chi-Huey Wong | Oligosaccharide enzyme substrates and inhibitors: method and compositions |
IL101243A (en) | 1991-03-20 | 1999-12-22 | Merck & Co Inc | Pharmaceutical preparations for the treatment of benign prostatic hyperplasia containing steroid history |
US5994362A (en) | 1992-03-11 | 1999-11-30 | Merck & Co., Inc. | Method of treatment for prostatic cancer |
US5171081A (en) | 1992-05-29 | 1992-12-15 | Pita Joe W | Chemiluminescent reactive vessel |
US5323907A (en) | 1992-06-23 | 1994-06-28 | Multi-Comp, Inc. | Child resistant package assembly for dispensing pharmaceutical medications |
CA2138020C (en) | 1992-06-23 | 1999-02-16 | Eric A. Johnson | Pharmaceutical composition containing botulinum b complex |
US5353961A (en) | 1993-01-15 | 1994-10-11 | Reseal International Limited Partnership | Dual chamber dispenser |
US5395619A (en) | 1993-03-03 | 1995-03-07 | Liposome Technology, Inc. | Lipid-polymer conjugates and liposomes |
AU7097094A (en) | 1993-06-01 | 1994-12-20 | Enzon, Inc. | Carbohydrate-modified polymer conjugates with erythropoietic activity |
US5395326A (en) | 1993-10-20 | 1995-03-07 | Habley Medical Technology Corporation | Pharmaceutical storage and mixing syringe having high pressure assisted discharge |
US5643575A (en) | 1993-10-27 | 1997-07-01 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
US5919455A (en) | 1993-10-27 | 1999-07-06 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
US5446090A (en) | 1993-11-12 | 1995-08-29 | Shearwater Polymers, Inc. | Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules |
US5766627A (en) | 1993-11-16 | 1998-06-16 | Depotech | Multivescular liposomes with controlled release of encapsulated biologically active substances |
US5795569A (en) | 1994-03-31 | 1998-08-18 | Amgen Inc. | Mono-pegylated proteins that stimulate megakaryocyte growth and differentiation |
WO1995026746A1 (en) | 1994-03-31 | 1995-10-12 | Amgen Inc. | Compositions and methods for stimulating megakaryocyte growth and differentiation |
US6093563A (en) | 1994-07-08 | 2000-07-25 | Ibex Technologies R And D, Inc. | Chondroitin lyase enzymes |
US5993850A (en) * | 1994-09-13 | 1999-11-30 | Skyepharma Inc. | Preparation of multivesicular liposomes for controlled release of encapsulated biologically active substances |
US5496284A (en) | 1994-09-27 | 1996-03-05 | Waldenburg; Ottfried | Dual-chamber syringe & method |
US5824784A (en) | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
DE4445969C1 (de) | 1994-12-22 | 1996-03-14 | Schott Glaswerke | Spritzenzylinder für eine Zweikammer-Fertigspritze, Zweikammer-Fertigspritze und Verfahren zum Herstellen und Füllen derselben |
US5932462A (en) | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
US5747027A (en) | 1995-04-07 | 1998-05-05 | The Regents Of The University Of California | BH55 hyaluronidase |
GB9508204D0 (en) | 1995-04-21 | 1995-06-07 | Speywood Lab Ltd | A novel agent able to modify peripheral afferent function |
CA2193354A1 (en) * | 1995-04-25 | 1996-10-31 | Catherine Lee | Composition containing collagenase and chymopapain for isolating hepatocytes and pancreatic islet cells |
US6129761A (en) | 1995-06-07 | 2000-10-10 | Reprogenesis, Inc. | Injectable hydrogel compositions |
GB9511909D0 (en) | 1995-06-12 | 1995-08-09 | Microbiological Res Authority | Vaccine |
US5672662A (en) | 1995-07-07 | 1997-09-30 | Shearwater Polymers, Inc. | Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications |
US5872150A (en) | 1996-03-01 | 1999-02-16 | Merck & Co., Inc. | Treatment of prostate disease with a nonsteroidal anti-androgenic compound |
US5837265A (en) | 1996-03-08 | 1998-11-17 | The Regents Of The University Of California | Chemically-modified clostridiatoxin with improved properties |
EP0955999B1 (en) | 1996-08-19 | 2001-12-05 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Novel liposome complexes for increased systemic delivery |
GB9617671D0 (en) | 1996-08-23 | 1996-10-02 | Microbiological Res Authority | Recombinant toxin fragments |
US6214966B1 (en) | 1996-09-26 | 2001-04-10 | Shearwater Corporation | Soluble, degradable poly(ethylene glycol) derivatives for controllable release of bound molecules into solution |
US5997899A (en) | 1996-10-01 | 1999-12-07 | Skyepharma Inc. | Method for producing liposomes with increased percent of compound encapsulated |
US6193963B1 (en) | 1996-10-17 | 2001-02-27 | The Regents Of The University Of California | Method of treating tumor-bearing patients with human plasma hyaluronidase |
US5939070A (en) | 1996-10-28 | 1999-08-17 | Wisconsin Alumni Research Foundation | Hybrid botulinal neurotoxins |
US6258351B1 (en) | 1996-11-06 | 2001-07-10 | Shearwater Corporation | Delivery of poly(ethylene glycol)-modified molecules from degradable hydrogels |
US5891467A (en) | 1997-01-31 | 1999-04-06 | Depotech Corporation | Method for utilizing neutral lipids to modify in vivo release from multivesicular liposomes |
US5990237A (en) | 1997-05-21 | 1999-11-23 | Shearwater Polymers, Inc. | Poly(ethylene glycol) aldehyde hydrates and related polymers and applications in modifying amines |
US7449192B2 (en) | 1997-07-15 | 2008-11-11 | The Regents Of The University Of Colorado | Use of neurotoxin therapy for treatment of urologic and related disorders related to neurogenic bladder dysfunction |
CA2505930C (en) | 1997-07-15 | 2008-01-29 | Richard A. Schmidt | Use of botulinum toxin in the preparation of a pharmaceutical composition for treating urinary retention |
US7455845B2 (en) | 1997-07-15 | 2008-11-25 | The Regents Of The University Of Colorado | Use of neurotoxin therapy for treatment of urologic and related disorders related to lowering elevated bladder pressure |
US6106858A (en) | 1997-09-08 | 2000-08-22 | Skyepharma, Inc. | Modulation of drug loading in multivescular liposomes |
US6306432B1 (en) * | 1997-09-08 | 2001-10-23 | Chiron Corporation | High and low load formulations of IGF-I in multivesicular liposomes |
US5971953A (en) | 1998-01-09 | 1999-10-26 | Bachynsky; Nicholas | Dual chamber syringe apparatus |
US6448369B1 (en) | 1997-11-06 | 2002-09-10 | Shearwater Corporation | Heterobifunctional poly(ethylene glycol) derivatives and methods for their preparation |
IL135989A0 (en) | 1997-11-14 | 2001-05-20 | Skyepharma Inc | Processes for the production of multivesicular liposomes |
US20040081659A1 (en) | 1997-12-02 | 2004-04-29 | Merck & Co., Inc. | Conjugates useful in the treatment of prostate cancer |
US5985263A (en) | 1997-12-19 | 1999-11-16 | Enzon, Inc. | Substantially pure histidine-linked protein polymer conjugates |
ATE399809T1 (de) | 1998-03-12 | 2008-07-15 | Nektar Therapeutics Al Corp | Verfahren zur herstellung von polymerkonjugaten |
US5955368A (en) | 1998-04-06 | 1999-09-21 | Wisconsin Alumni Research Foundation | Expression system for clostridium species |
EP1095243A2 (en) | 1998-07-03 | 2001-05-02 | Neles Field Controls Oy | Method and arrangement for measuring fluid |
US6420339B1 (en) | 1998-10-14 | 2002-07-16 | Amgen Inc. | Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility |
US6331251B1 (en) | 1999-06-10 | 2001-12-18 | Envirogen, Inc. | System and method for withdrawing permeate through a filter and for cleaning the filter in situ |
CZ299516B6 (cs) | 1999-07-02 | 2008-08-20 | F. Hoffmann-La Roche Ag | Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem |
PE20010288A1 (es) | 1999-07-02 | 2001-03-07 | Hoffmann La Roche | Derivados de eritropoyetina |
US6461802B1 (en) | 1999-08-02 | 2002-10-08 | Agfa-Gevaert | Adhesive layer for polyester film |
US6428785B1 (en) | 1999-10-28 | 2002-08-06 | Immunolytics Inc. | Method and composition for treating prostate cancer |
US6200573B1 (en) | 1999-12-03 | 2001-03-13 | Starcor Pharmaceuticals, Inc. | Method of medical management for lower urinary tract symptoms and benign prostatic hyperplasia |
DK1259562T3 (da) | 1999-12-22 | 2006-04-18 | Nektar Therapeutics Al Corp | Sterisk hindrede derivater af vandoplöselige polymerer |
US6413507B1 (en) | 1999-12-23 | 2002-07-02 | Shearwater Corporation | Hydrolytically degradable carbamate derivatives of poly (ethylene glycol) |
CA2395902A1 (en) | 1999-12-28 | 2001-07-05 | Asger Lau Dalmose | Dual chamber syringe with a dual function piston |
US7138127B1 (en) | 2000-01-19 | 2006-11-21 | Allergan, Inc. | Clostridial toxin derivatives and methods for treating pain |
US20030212021A1 (en) | 2001-01-25 | 2003-11-13 | Frost Gregory I. | Myeloid colony stimulating factor and uses thereof |
US20030118598A1 (en) | 2000-02-08 | 2003-06-26 | Allergan, Inc. | Clostridial toxin pharmaceutical compositions |
US6602498B2 (en) | 2000-02-22 | 2003-08-05 | Shearwater Corporation | N-maleimidyl polymer derivatives |
US6586398B1 (en) | 2000-04-07 | 2003-07-01 | Amgen, Inc. | Chemically modified novel erythropoietin stimulating protein compositions and methods |
DE60122259T2 (de) | 2000-04-10 | 2006-12-07 | Samsung Electronics Co., Ltd., Suwon | Verfahren zur messung der verwirrungsrate eines gemeinsames paketkanals in einem cdma-übertragungssystem |
DE10024752A1 (de) * | 2000-05-16 | 2001-11-29 | Ben Pfeifer | Mittel und Vorrichtung zur Behandlung von Prostata-Erkrankungen |
DE60129432T2 (de) | 2000-05-16 | 2008-04-17 | Bolder Biotechnology, Inc., Louisville | Verfahren zur rückfaltung von proteinen mit freien cysteinresten |
US6306423B1 (en) | 2000-06-02 | 2001-10-23 | Allergan Sales, Inc. | Neurotoxin implant |
US7491799B2 (en) | 2000-07-21 | 2009-02-17 | Allergan, Inc. | Modified botulinum neurotoxins |
US7223577B2 (en) | 2000-11-17 | 2007-05-29 | Allergan, Inc. | Post-translational modifications and Clostridial neurotoxins |
WO2002049673A2 (en) | 2000-12-20 | 2002-06-27 | F. Hoffmann-La Roche Ag | Conjugates of erythropoietin (pep) with polyethylene glycol (peg) |
TWI246524B (en) | 2001-01-19 | 2006-01-01 | Shearwater Corp | Multi-arm block copolymers as drug delivery vehicles |
US6745776B2 (en) * | 2001-04-10 | 2004-06-08 | David B. Soll | Methods for reducing postoperative intraocular pressure |
WO2002096368A2 (en) | 2001-05-31 | 2002-12-05 | Skyepharma Inc. | Encapsulation of nanosuspensions in liposomes and microspheres |
US7015253B2 (en) | 2001-07-10 | 2006-03-21 | American Medical Systems, Inc. | Regimen for treating prostate tissue and surgical kit for use in the regimen |
US6908963B2 (en) | 2001-10-09 | 2005-06-21 | Nektar Therapeutics Al, Corporation | Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith |
AU2002352524B2 (en) | 2001-11-07 | 2007-10-04 | Nektar Therapeutics | Branched polymers and their conjugates |
US6972005B2 (en) | 2002-05-10 | 2005-12-06 | Boehm Jr Frank H | Dual chamber syringe and dual lumen needle |
KR20040040782A (ko) | 2002-11-08 | 2004-05-13 | 선바이오(주) | 신규한 헥사-암 폴리에틸렌글리콜과 유도체 및 그의합성방법 |
EP1594523B1 (en) | 2002-12-20 | 2009-03-25 | Botulinum Toxin Research Associates, Inc. | Pharmaceutical compositions comprising botulinum toxin and human serum albumin |
US7627479B2 (en) | 2003-02-21 | 2009-12-01 | Motionpoint Corporation | Automation tool for web site content language translation |
ES2911435T3 (es) | 2003-02-26 | 2022-05-19 | Nektar Therapeutics | Conjugados de polímero-resto de Factor VIII |
US20090123367A1 (en) | 2003-03-05 | 2009-05-14 | Delfmems | Soluble Glycosaminoglycanases and Methods of Preparing and Using Soluble Glycosaminoglycanases |
US7871607B2 (en) | 2003-03-05 | 2011-01-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
PL2405015T3 (pl) | 2003-03-05 | 2016-09-30 | Rozpuszczalna glikoproteina o aktywności hialuronizady (sHASEGP), sposób jej wytwarzania, jej zastosowania i zawierające ją kompozycje farmaceutyczne | |
US20060104968A1 (en) * | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
US7610156B2 (en) | 2003-03-31 | 2009-10-27 | Xencor, Inc. | Methods for rational pegylation of proteins |
KR100512483B1 (ko) | 2003-05-07 | 2005-09-05 | 선바이오(주) | 신규한 폴리에틸렌글리콜-말레이미드 유도체의 합성방법 |
CA2510040C (en) | 2003-05-23 | 2012-01-03 | Nektar Therapeutics Al, Corporation | Polymeric reagents and polymer-biomolecule conjugates comprising carbamate linkages |
US7452697B2 (en) | 2003-09-25 | 2008-11-18 | Allergan, Inc. | Chromatographic method and system for purifying a botulinum toxin |
US7148041B2 (en) | 2003-09-25 | 2006-12-12 | Allergan, Inc. | Animal product free media and processes for obtaining a botulinum toxin |
US20060228404A1 (en) | 2004-03-04 | 2006-10-12 | Anderson Daniel G | Compositions and methods for treatment of hypertrophic tissues |
US20050287180A1 (en) | 2004-06-15 | 2005-12-29 | Chen Andrew X | Phospholipid compositions and methods for their preparation and use |
EP1807051A2 (en) * | 2004-11-05 | 2007-07-18 | Inex Pharmaceuticals Corporation | Compositions and methods for stabilizing liposomal camptothecin formulations |
US7465457B2 (en) | 2005-04-14 | 2008-12-16 | Wisconsin Alumni Research Foundation | Method for preparing botulinum neurotoxin type A light chain |
US7758594B2 (en) | 2005-05-20 | 2010-07-20 | Neotract, Inc. | Devices, systems and methods for treating benign prostatic hyperplasia and other conditions |
WO2006133553A1 (en) | 2005-06-14 | 2006-12-21 | Protox Therapeutics Incorporated | Method of treating or preventing benign prostatic hyperplasia using modified pore-forming proteins |
CA2612768A1 (en) | 2005-06-30 | 2007-01-11 | Mallinckrodt Inc. | Dual chamber syringe |
ATE463506T1 (de) | 2005-09-19 | 2010-04-15 | Allergan Inc | Mit clostriedientoxin aktivierbare clostridientoxine |
US20080145415A1 (en) * | 2006-04-21 | 2008-06-19 | Lanfranco Callegaro | Bioresorbable Fillers Constituted by Phospholipid Liposomes and Hyaluronic Acid and/or the Derivatives Thereof |
ES2520765T3 (es) | 2007-02-15 | 2014-11-11 | Allergan, Inc. | Uso de toxina botulínica para el tratamiento de hiperhidrosis |
US9107815B2 (en) | 2008-02-22 | 2015-08-18 | Allergan, Inc. | Sustained release poloxamer containing pharmaceutical compositions |
WO2009111066A1 (en) | 2008-03-06 | 2009-09-11 | Halozyme, Inc. | Large-scale production of soluble hyaluronidase |
KR20160052812A (ko) | 2008-04-14 | 2016-05-12 | 할로자임, 아이엔씨 | 히알루로난 관련 질환 및 상태 치료용 변형된 히알루로니다제 및 그 용도 |
EA036569B1 (ru) * | 2008-12-09 | 2020-11-24 | Галозим, Инк. | Способ получения полипептида гиалуронидазы ph20 |
WO2010138918A1 (en) * | 2009-05-29 | 2010-12-02 | Pacira Pharmaceuticals, Inc. | Hyaluronidase as an adjuvant for increasing the injection volume and dispersion of large diameter synthetic membrane vesicles containing a therapeutic agent |
CN102933200B (zh) | 2009-12-18 | 2015-11-25 | 莱迪杜德制药公司 | 包含磷脂的单相凝胶组合物 |
EP2595624B1 (en) | 2010-07-20 | 2018-01-31 | Halozyme, Inc. | Methods of treatment or prevention of the adverse side-effects associated with administration of an anti-hyaluronan agent |
ES2634669T3 (es) | 2011-02-08 | 2017-09-28 | Halozyme, Inc. | Composición y formulación lipídica de una enzima de degradación de hialuronano y uso de la misma para el tratamiento de la hiperplasia benigna de próstata |
-
2012
- 2012-02-08 ES ES15158288.9T patent/ES2634669T3/es active Active
- 2012-02-08 WO PCT/US2012/024376 patent/WO2012109387A1/en active Application Filing
- 2012-02-08 EP EP12704217.4A patent/EP2672958A1/en not_active Withdrawn
- 2012-02-08 JP JP2013552741A patent/JP2014510045A/ja active Pending
- 2012-02-08 EP EP15158288.9A patent/EP2907504B1/en active Active
-
2013
- 2013-02-19 US US13/815,311 patent/US9333244B2/en active Active
-
2017
- 2017-02-22 JP JP2017030692A patent/JP6403819B2/ja active Active
-
2018
- 2018-07-11 JP JP2018131504A patent/JP2018172429A/ja active Pending
-
2020
- 2020-06-24 JP JP2020108943A patent/JP6831488B2/ja active Active
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2014510045A5 (ja) | ||
Zhang et al. | High-generation polycationic dendrimers are unusually effective at disrupting anionic vesicles: membrane bending model | |
Bai et al. | Preparation and characterization of endolysin-containing liposomes and evaluation of their antimicrobial activities against gram-negative bacteria | |
Oninla et al. | Acid sphingomyelinase activity is regulated by membrane lipids and facilitates cholesterol transfer by NPC2 [S] | |
Farrera et al. | It takes two to tango: Understanding the interactions between engineered nanomaterials and the immune system | |
Tachi et al. | Position-dependent hydrophobicity of the antimicrobial magainin peptide affects the mode of peptide− lipid interactions and selective toxicity | |
Connor et al. | pH-sensitive immunoliposomes as an efficient and target-specific carrier for antitumor drugs | |
Abdul-Hammed et al. | Role of endosomal membrane lipids and NPC2 in cholesterol transfer and membrane fusion [S] | |
Semple et al. | Influence of cholesterol on the association of plasma proteins with liposomes | |
Linke et al. | Stimulation of acid sphingomyelinase activity by lysosomal lipids and sphingolipid activator proteins | |
Arnold et al. | Lipid regulation of CTP: phosphocholine cytidylyltransferase: electrostatic, hydrophobic, and synergistic interactions of anionic phospholipids and diacylglycerol | |
Grant et al. | DRV liposomal bupivacaine: preparation, characterization, and in vivo evaluation in mice | |
Alonso et al. | Lipids favoring inverted phase enhance the ability of aerolysin to permeabilize liposome bilayers | |
Sandhoff | Neuronal sphingolipidoses: membrane lipids and sphingolipid activator proteins regulate lysosomal sphingolipid catabolism | |
Troutier et al. | New insights into self-organization of a model lipid mixture and quantification of its adsorption on spherical polymer particles | |
Won et al. | Imaging the membrane lytic activity of bioactive peptide latarcin 2a | |
Østrem et al. | Secretory phospholipase A2 responsive liposomes exhibit a potent anti-neoplastic effect in vitro, but induce unforeseen severe toxicity in vivo | |
Urbina et al. | Effects of bilayer composition and physical properties on the phospholipase C and sphingomyelinase activities of Clostridium perfringens α-toxin | |
Allon et al. | A new liposome-based gene delivery system targeting lung epithelial cells using endothelin antagonist | |
Breiden et al. | Acid sphingomyelinase, a lysosomal and secretory phospholipase C, is key for cellular phospholipid catabolism | |
Derde et al. | Dry-heating of lysozyme increases its activity against Escherichia coli membranes | |
Urbina et al. | Unexpected wide substrate specificity of C. perfringens α-toxin phospholipase C | |
Abe et al. | The role of negatively charged lipids in lysosomal phospholipase A2 function | |
Ciaffoni et al. | Saposin B binds and transfers phospholipids | |
Santi et al. | Protein delivery by peptide-based stealth liposomes: A biomolecular insight into enzyme replacement therapy |